U.S. Infections Imaging Market Size, Share, Growth, Trends | Report 2022-2030
Market Synopsis
Infections are diagnosed by laboratory tests such as blood tests, urine and stool tests, throat swabs, lumbar puncture, etc. Other techniques include imaging scans and biopsies. Identification of most areas of infection has become quick and easy due to the advent of high-resolution cross-sectional imaging. Molecular imaging in the past was mainly used by labeling leucocytes with radioactive agents to identify infections. With the development of functional nuclear imaging, bacterial and viral metabolism can also be imaged directly for potential identification of early infection. Cross-sectional imaging is used routinely to identify and treat sources of infection in patients with fever, leucocytosis, or unexplained hemodynamic instability. Although ultrasound is preferred for the identification of biliary or hepatic sepsis, computed tomography (CT) has proved to be accurate for the identification and treatment of intra-abdominal fluid collections and abscesses.
Nuclear medicine is an effective tool in imaging as it identifies crucial complementary information, allowing visualization of infectious pathophysiology beyond morphologic imaging. There are numerous research activities conducted using nuclear medicine techniques as detection of metabolic abnormalities is done precisely by these techniques and it preceded morphological changes identified by structural imaging. Nuclear medicine techniques are also showing promising results in the diagnosis of COVID-19 infection. Thus nuclear medicine holds a great growth opportunity as an identification tool in the infection imaging market.
Market Influencer
The guidelines laid down by the American and European Nuclear Medicine Society, state that fever of unknown origin, sarcoidosis, and vasculitis are among the major clinical indications that benefit from nuclear medicine procedures, specifically from performing positron emission tomography (PET) using 18F fluoro-deoxy-glucose with CT (FDG PET/CT). The cost of using these techniques saved nearly 5000 to 11000 USD per patient for diagnosis of fever of unknown origin.In the last 3 decades, the mortality rate of infective endocarditis has remained steady i.e. ~30%.The use of PET/CT technique is still being studied for the effective diagnosis of endocarditis, however, it is proved to be effective in PV endocarditis identification.The American Society of Nuclear Cardiology recommends performing FDG/PET CTA to detect structural vascular changes and complications caused by vasculitis. Osteomyelitis shows nonspecific symptoms, and physical examination and laboratory results often delay identification. Thus, techniques like unenhanced MRI can be used to identify tissue changes and the involvement of surrounding bones within two days of infection onset. However, nuclear medicine test provides high image sensitivity and enables accurate diagnosis. Hence, it is advent that, nuclear medicine is an effective tool in the diagnosis of numerous infections showing low symptoms and reduced sensitivity to other imaging modalities. Other infections that are studied for effective diagnosis using nuclear medicine and other imaging modalities include, acute appendicitis, musculoskeletal infection, cardiovascular inflammation, pneumonia, tuberculosis, endocarditis, myocarditis, LVAD infections, Crohn’s disease, colitis, atherosclerosis, coronary artery disease, and many others.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on U.S. Infections Imaging Market
5.1. COVID-19 Landscape: U.S. Infections Imaging Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global U.S. Infections Imaging Market, By Imaging Modality
8.1. U.S. Infections Imaging Market, by Imaging Modality, 2022-2030
8.1.1 X-rays
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Mammography
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. CT scans
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Nuclear Medicine
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. MRI scans
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Ultrasound
8.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global U.S. Infections Imaging Market, By Indication
9.1. U.S. Infections Imaging Market, by Indication, 2022-2030
9.1.1. Acute Appendicitis
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Musculoskeletal Infection
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Cardivascular Inflammation
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Pneumonia
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Tuberculosis
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Endocarditis
9.1.6.1. Market Revenue and Forecast (2017-2030)
9.1.7. LVAD Infections
9.1.7.1. Market Revenue and Forecast (2017-2030)
9.1.8. Crohn’s Disease
9.1.8.1. Market Revenue and Forecast (2017-2030)
9.1.9. Colitis
9.1.9.1. Market Revenue and Forecast (2017-2030)
9.1.10. Atherosclerosis
9.1.10.1. Market Revenue and Forecast (2017-2030)
9.1.11. Coronary Artery Disease
9.1.11.1. Market Revenue and Forecast (2017-2030)
9.1.12. Fever of Unknown Origin
9.1.12.1. Market Revenue and Forecast (2017-2030)
9.1.13. Osteomyelitis
9.1.13.1. Market Revenue and Forecast (2017-2030)
9.1.14. Skin and Soft Tissue Infection
9.1.14.1. Market Revenue and Forecast (2017-2030)
9.1.15. Atheroscierosis
9.1.15.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global U.S. Infections Imaging Market, By End-use
10.1. U.S. Infections Imaging Market, by End-use, 2022-2030
10.1.1. Hospital
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Diagnostics Imaging Centers
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global U.S. Infections Imaging Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.1.2. Market Revenue and Forecast, by Indication (2017-2030)
11.1.3. Market Revenue and Forecast, by End-use (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Indication (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Indication (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.2.2. Market Revenue and Forecast, by Indication (2017-2030)
11.2.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Indication (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Indication (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Indication (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Indication (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.3.2. Market Revenue and Forecast, by Indication (2017-2030)
11.3.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Indication (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Indication (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Indication (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Indication (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.4.2. Market Revenue and Forecast, by Indication (2017-2030)
11.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Indication (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Indication (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Indication (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Indication (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.5.2. Market Revenue and Forecast, by Indication (2017-2030)
11.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Indication (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Imaging Modality (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Indication (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 12. Company Profiles
12.1. GE Healthcare
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Curium
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bracco
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Lantheus Medical Imaging, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers